VentureBeat » Co:Singulex

Singulex lands $19M for diagnostic systems

Camille Ricketts — Wed, 14 Jan 2009 23:19:38 +0000

Singulex, an Alameda, Calif.-based biotech firm, just raised $19 million in fifth-round funding to commercialize technology that uses protein biomarkers to diagnose cardiovascular and other disorders. Already in clinical trials, its system gauges changes in biomarker levels in the bloodstream to give doctors information on the progression and potential management of disease. Singulex has already forged partnerships with several pharmaceutical companies using the system to measure the effects of various drugs during clinical trials.

The recent investment round was led by Jafco Ventures and included OrbiMed Advisors and Fisk Ventures. This brings the company’s total capital raised to $50 million since its inception in 2002.

Posted in VentureBeat

Biomarker-diagnostics developer Singulex validates $19M

David P. Hamilton — Thu, 07 Jun 2007 15:36:39 +0000

Hayward, Calif.-based Singulex, a developer of sensitive molecular-detection systems, raised $19 million in a fourth funding round. The company’s release is here.

The company is developing an analysis system, called Erenna, plus related “assays,” or specially designed biochemical tests, that are designed to detect individual protein molecules in biological samples such as blood. Such tests could be useful for detecting or diagnosing disease, monitoring the effect of drug treatment, and other research and diagnostic purposes. For instance, Singulex says its system can identify previously undetectable cellular levels of cardiac troponin I, a protein biomarker that can be used to measure tissue damage following a heart attack. The company claims that its system can actually count the number of proteins in a given sample.

Singulex already offers its services to research centers at biotech and pharmaceutical companies, and hopes also to break into the field of molecular diagnostics — a much more challenging and heavily regulated area.

The round was led by OrbiMed Advisors, joined by existing investors Fisk Ventures (a venture fund of H. Fisk Johnson, CEO of S.C. Johnson & Son), Prolog Ventures, and Advantage Capital. Singulex has raised $31.6 million to date, according to VentureWire (subscription required).

Molecular detection Co., Singulex, raises $10.5M

Editor — Wed, 20 Sep 2006 13:37:14 +0000

Singulex, a Hayward company developing “bio-markers” to detect the presence in the body of certain proteins that might suggest disease, said it has raised $10.5 million in series C and debt financing deals.

It also said it has added Mickey Urdea, Ph.D. to its board of directors and has successfully completed several commercial pilot studies with research labs and pharmaceutical partners using the company’s “Zept x” molecular detection system.

The company said it has opened a 6,000 square foot commercial operation facility in Hayward.

Singulex’ existing investors, Fisk Venture and Prolog Ventures were part of the latest financing round totaling $8 million, which was led by a new undisclosed investor, the company said.

The company also closed a one million dollar financing round from GE Capital and a one and a half million dollar debt financing from Bridge Bank, bringing the total amount raised to $10.5 million.

The product should hit the market in the first half of 2007, the company said.